Drug resistance

HIV drug resistance (HIVDR) poses a threat to future antiretroviral therapy success. Monitoring HIVDR patterns is of particular importance in populations such as sex workers (SWs), where documented HIV prevalence is between 34-89%, and in countries with limited therapeutic options.

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries.

Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS.

Hepatitis B virus (HBV)–HIV coinfections are becoming common with information on HBV genetic diversity and drug resistance still remaining elusive.

This second HIV drug resistance (HIVDR) report provides an update on recent population levels of HIVDR covering the period 2014–2016.

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries.

Tuberculosis disproportionately affects hard-to-reach populations, such as homeless people, migrants, refugees, prisoners, or drug users. These people often face challenges in accessing quality health care.

Although the number of deaths worldwide from tuberculosis—a disease caused by the bacterium Mycobacterium tuberculosis—fell by 22% between 2000 and 2015, it remains humanity’s biggest infectious killer and one of the top ten causes of all deaths.

The Stop TB Partnership today launched its World TB Day website which has the full spectrum of downloadable communications materials.

The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments.